Azenta(AZTA) - 2021 Q2 - Quarterly Report

Revenue and Growth - Revenue for the three months ended March 31, 2021 increased 30% to $286.6 million compared to the same period in the prior fiscal year[179] - Revenue for the six months ended March 31, 2021 increased 24% to $536.1 million compared to the same period in the prior fiscal year[180] - Revenue for the three months ended March 31, 2021, was $286.6 million, an increase of 30% compared to $220.2 million for the same period in the prior fiscal year[187] - Brooks Semiconductor Solutions Group segment reported revenue of $157.1 million for the three months ended March 31, 2021, a 26% increase from $124.9 million in the prior year[188] - Brooks Life Sciences Products segment revenue increased by 69% to $52.4 million for the three months ended March 31, 2021, compared to $31.0 million in the prior year[189] - Revenue generated outside the United States was $182.2 million, or 64% of total revenue, for the three months ended March 31, 2021, compared to 61% in the prior year[194] - The acquisitions of RURO and THB contributed $4.0 million in revenue for the six months ended March 31, 2021[193] Profitability and Margins - Gross margin for the three months ended March 31, 2021 was 44.4%, up from 41.0% in the corresponding period of the prior fiscal year, resulting in an increase in gross profit of $37.0 million[179] - Gross margin for the six months ended March 31, 2021 was 44.8%, up from 40.7% in the corresponding period of the prior fiscal year, resulting in an increase in gross profit of $65.1 million[180] - Operating income for the second quarter of fiscal year 2021 was $30.5 million, compared to $14.6 million for the same period in the prior fiscal year[179] - Operating income for the three months ended March 31, 2021, was $30.5 million, a 109% increase from $14.6 million in the same period of the prior fiscal year[195] - Brooks Semiconductor Solutions Group segment reported gross margins of 44.2% for the three months ended March 31, 2021, an increase of 5.3 percentage points from 38.9% in the prior fiscal year[208] - Brooks Life Sciences Products segment reported gross margins of 45.9% for the three months ended March 31, 2021, up 2.8 percentage points from 43.2% in the prior fiscal year[209] - Brooks Life Sciences Services segment reported gross margins of 43.8% for the three months ended March 31, 2021, a decrease of 0.2 percentage points from 44.0% in the prior fiscal year[210] Expenses and Financial Activities - Research and development expenses increased to $16.9 million for the three months ended March 31, 2021, compared to $15.3 million in the prior fiscal year[214] - Selling, general and administrative expenses rose to $79.7 million for the three months ended March 31, 2021, compared to $59.8 million in the prior fiscal year, driven by $19.9 million increase[218] - Interest expense decreased to $0.5 million for the three months ended March 31, 2021, down from $0.7 million in the prior fiscal year[225] - Cash used in investing activities was $42.4 million during the six months ended March 31, 2021, which included $25.5 million for capital expenditures and $15.1 million for an acquisition[241] - Cash outflows for financing activities totaled $13.3 million during the six months ended March 31, 2021, primarily due to cash dividend payments of $14.9 million[242] Cash and Liquidity - Cash, cash equivalents, restricted cash, and marketable securities were $334.3 million at March 31, 2021, an increase of $28.6 million from $305.7 million at September 30, 2020[181] - As of March 31, 2021, the company had cash and cash equivalents of $320.1 million, an increase from $295.6 million as of September 30, 2020, representing a growth of 8.5%[236] - Cash inflows from operating activities for the six months ended March 31, 2021, were $77.9 million, primarily driven by $86.5 million in earnings, including $49.8 million in net income[240] - The company had non-cancellable commitments of $266.4 million as of March 31, 2021, including $230.1 million for inventory purchases[254] Foreign Currency and Interest Rate Exposure - Approximately 40% of total sales during the six months ended March 31, 2021, were denominated in currencies other than the U.S. dollar, primarily by foreign subsidiaries[259] - A hypothetical 10% change in foreign exchange rates would result in an approximate change of $0.6 million and $3.8 million in net income for the six months ended March 31, 2021 and 2020, respectively[262] - Liquid assets denominated in non-functional currencies were approximately $92.8 million and $142.9 million at March 31, 2021 and September 30, 2020, respectively[260] - A hypothetical 100 basis point change in interest rates would result in a $0.3 million change in interest expense for the six months ended March 31, 2021[257] Corporate Developments and Future Outlook - The company invested more than 29% of its cumulative research and development spending in the life sciences market for the fiscal years ended 2020, 2019, and 2018[178] - The company launched the BioStore™ IIIv, which offers improved data management and sample security for vaccines and biologics stored at -80°C[178] - The company continues to focus on developing processes and technologies to streamline sample to data workflow in the life sciences sector[178] - The semiconductor solutions business continues to supply critical chip manufacturing equipment and support services globally, with no substantial negative impact from the COVID-19 pandemic on financial results[167] - The company expects to incur an additional $43 million to $47 million in capital expenditures related to the construction of a facility in Suzhou, China, over the next four years[243] Legal and Compliance - The company believes that none of the legal proceedings will have a material adverse effect on its consolidated financial condition or results of operations[266] - There were no changes in internal control over financial reporting that materially affected the company during the most recent fiscal quarter[264]